Laserfiche WebLink
WAC 388-877B-0440 <br /> Substance use disorder opiate substitution treatment services—Program physician responsibility. <br /> An agency providing substance use disorder opiate substitution treatment services must ensure the <br /> program physician, or the medical practitioner under supervision of the program physician, performs <br /> and meets the following: <br /> (1)The program physician or medical practitioner under supervision of the program physician: <br /> (a) Is responsible to verify an individual is currently addicted to an opioid drug and that the person <br /> became addicted at least twelve months before admission to treatment. <br /> (b) May waive the twelve month requirement in (a)of this subsection upon receiving <br /> documentation that the individual: <br /> (i) Was released from a penal institution, if the release was within the previous six months; <br /> (ii) Is pregnant;or <br /> (iii)Was previously treated within the previous twenty-four months. <br /> (2)A physical evaluation must be completed on the individual before admission that includes the <br /> determination of opiate physical addiction consistent with the Diagnostic and Statistical Manual (DSM-5) <br /> criteria,and an assessment for appropriateness for Sunday and holiday take-home medication. <br /> Information on the DSM-5 can be found on the American Psychiatric Association's public website at <br /> www.DSM5.org. <br /> (3)A review must be completed by the department of health prescription drug monitoring program <br /> data on the individual: <br /> (a) At admission; <br /> (b)Annually after the date of admission; and <br /> (c)Subsequent to any incidents of concern. <br /> (4)All relevant facts concerning the use of the opioid drug must be clearly and adequately explained <br /> to each individual. <br /> (5)Current written and verbal information must be provided to pregnant individuals, before the <br /> initial prescribed dosage regarding: <br /> (a)The concerns of possible addiction, health risks,and benefits the opiate substitution medication <br /> may have on the individual and the fetus. <br /> (b) The risk of not initiating opiate substitution medication on the individual and the fetus. <br /> (c) Referral options to address neonatal abstinence syndrome for the baby. <br /> (6) Each individual voluntarily choosing to receive maintenance treatment must sign an informed <br /> consent to treatment. <br /> (7) Within fourteen days of admission, a medical examination must be completed that includes: <br /> 12 <br />